Information Hub

Clinical News

2020-08-21

A new IDH1/2 inhibitor for mutated IDH1/2 low-grade glioma

In a phase I study, the anti-tumor activity of vorasidenib (VOR; AG-881) was demonstrated in mutated IDH1/2 low-grade glioma.

Source:

J Clin Oncol

2020-08-21

A new FGFR inhibitor for intrahepatic cholangiocarcinoma treatment

In a phase 2 study, futibatinib showed anti-tumor efficacy in chemotherapy-treated intrahepatic cholangiocarcinoma with FGFR2 fusion

Source:

J Clin Oncol

2020-08-21

ESR1 Mutation as a Prediction Marker for 1st-line AI plus CDK4/6 Inhibitor in HR+ Breast Cancer Patients

In phase 3 PADA-1 study, HR+ breast cancer patients with an ESR1 mutation showed worse outcomes in response to the 1st-line combination therapy of AI and palbociclib. Moreover, the reduction of plasma ESR1 mutation ctDNA level in the early stage of treatm

Source:

J Clin Oncol

2020-07-22

Capmatinib showed anti-tumor activity in MET-amplified advanced NSCLC

MET amplification is one of the driver genetic alterations in advanced NSCLC. In a phase II study, the anti-tumor activity of capmatinib was demonstrated in treatment-naïve and pretreated patients with MET-amplified advanced NSCLC.

Source:

J Clin Oncol

2020-07-22

LRP1B pathogenic mutations were associated with clinical benefits on immunotherapy treatment

The immunotherapy-related biomarkers other than PD-L1, MSI-H/dMMR or TMB are still under development. A study analyzed the immunotherapy clinical outcome in cancer patients with LRP1B mutations. The results indicated the LRP1B pathogenic mutations were as

Source:

J Clin Oncol

2020-07-22

Olaparib demonstrates anti-tumor activities in metastatic breast cancer patients harbored a mutation in homologous recombination repair pathway genes

Recently, phase 2 TBCRC 048 study results were published at the 2020 ASCO Virtual Scientific Program. This study aimed to investigate the activities of olaparib in metastatic breast cancer patients who have a homologous recombination repair gene mutation.

Source:

J Clin Oncol

2020-07-08

Is Immunotherapy Right for Me?

Cancer immunotherapy has been hailed as the most promising treatment against cancer in recent decades, but what exactly is immunotherapy? Is Immunotherapy right for me?

Source:

2020-07-07

Merck’s Keytruda grasps FDA approval again with TMB-H biomarker regardless of tumor type

Merck is proficient in the mechanism of immunotherapy, and after Keytruda's first approval in 2017 with MSI-H as biomarker regardless of where in the body cancer started, the same approval came in June 2020 with TMB-H, showing prospects in immunotherapy.

Source:

Fierce Pharma

2020-06-22

The role of POLE mutation in immunotherapy

POLE encodes a protein for DNA replication. This retrospective study revealed that pathogenic POLE mutations are correlated with TMB-H and associated with a better outcome of immunotherapy.

Source:

Garmezy B. et al. 2020 ASCO

2020-06-22

Tipifarnib shows preliminary activities in HRAS-mutant head and neck cancer and urothelial cancer

In two phase II studies published at the 2020 ASCO Virtual Scientific Program, tipifarnib demonstrated potential anti-tumor effect in head and neck cancer or urothelial cancer patients. All the recruited patients had an HRAS mutation.

Source:

J Clin Oncol 38: 2020